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Abstract
Aims: A reliable prediction tool is needed to identify acute coronary syndrome (ACS) patients with high mortality risk 
after their initial hospitalization.
Methods: EPICOR (long-tErm follow uP of antithrombotic management patterns In acute CORonary syndrome patients: 
NCT01171404) is a prospective cohort study of 10,568 consecutive hospital survivors after an ACS event (4943 ST-
segment elevation myocardial infarction (STEMI) and 5625 non-ST-elevation ACS (NSTE-ACS)). Of these cases, 65.1% 
underwent percutaneous coronary intervention (PCI) and 2.5% coronary artery bypass graft (CABG). Post-discharge 
mortality was recorded for up to two years. From over 50 potential predictor variables a new risk score for one-
year mortality was developed using forward stepwise Cox regression, and examined for goodness-of-fit, discriminatory 
power, and external validation.
Results: A total of 407 patients (3.9%) died within one year of discharge. We identified 12 highly significant independent 
predictors of mortality (in order of predictive strength): age, lower ejection fraction, poorer EQ-5D quality of life, elevated 
serum creatinine, in-hospital cardiac complications, chronic obstructive pulmonary disease, elevated blood glucose, male 
gender, no PCI/CABG after NSTE-ACS, low hemoglobin, peripheral artery disease, on diuretics at discharge. When 
combined into a new risk score excellent discrimination was achieved (c-statistic=0.81) and this was also validated on a 
large similar cohort (9907 patients) in Asia (c=0.78). For both STEMI and NSTE-ACS there was a steep gradient in one-
year mortality ranging from 0.5% in the lowest quintile to 18.2% in the highest decile. NSTE-ACS contributes over twice 
as many high-risk patients as STEMI.
Conclusions: Post-discharge mortality for ACS patients remains of concern. Our new user-friendly risk score available 
on www.acsrisk.org can readily identify who is at high risk.
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Introduction
Secondary prevention following an acute coronary syn-
drome (ACS) event is key as further ischemic events are 
common following the index event. Risk prediction tools 
have identified a number of factors which impact on risk of 
death and myocardial infarction (MI) following an ACS 
event. However, patient prognosis at hospital discharge 
continues to vary markedly, and post-discharge mortality 
remains a concern.1 Most risk scores include hospital mor-
tality in their estimations.2–4 There are no tools for risk cal-
culation of one-year mortality in hospital survivors. It is 
usually at the time of discharge that patients are asking 
about their prognosis. Therefore, there is a need for a reli-
able prediction tool to identify patients with high mortality 
risk, which may ultimately allow tailored treatment deci-
sions and improve prognosis. For instance, patients identi-
fied as at high risk may receive more frequent follow-up 
visits to facilitate their optimal care.
For patients experiencing an acute coronary event, a 
crucial time to assess their prognosis and future manage-
ment is at discharge from hospital. Hence, there is merit 
in developing a risk model that utilizes all the patient data 
on demographics, medical history, and patient status at, 
and during, admission, and at discharge. From a large 
representative international cohort study of consecutive 
patients with ACS who survived to discharge, we have 
related such detailed patient records to their subsequent 
follow-up for one year, expressing prognosis in terms of 
one-year mortality.
While ST segment elevation myocardial infarction 
(STEMI) and non-ST-elevation ACS (NSTE-ACS) patients 
have very different management and prognosis patterns 
during the in-hospital phase, from the moment of hospital 
discharge there is sufficient common ground and similarity 
of the key risk factors to combine both sets of patients into 
a single overall risk model.
There is an extensive literature on risk scores in ACS,5 
and their use is advocated by the European Society of 
Cardiology (ESC) guidelines for the management of 
NSTE-ACS.6 However, relatively little attention has 
been paid to risk assessment at hospital discharge, with 
just one previous risk score to date regarding six-month 
mortality post discharge.7 This is a valuable opportunity 
to quantify individual patient risk of mortality to one 
year after discharge following an acute coronary event 
hospitalization.
Methods
EPICOR (long-tErm follow uP of antithrombotic manage-
ment patterns In acute CORonary syndrome patients) is a 
prospective, international, observational, real-world prac-
tice, cohort study (NCT01171404) comprising consecutive 
patients, hospitalized for ACS within 24 h of symptom 
onset, who survived to hospital discharge.
In total, 10,568 patients with non-fatal ACS who sur-
vived until hospital discharge were enrolled between 
September 2010–March 2011 from 555 hospitals in 20 
countries across Europe and Latin America. A detailed 
account of the methodology of the study is described 
elsewhere.8,9
For external validation of our risk model, we used data 
from the EPICOR-Asia study10 (NCT01361386) which 
enrolled 12,993 patients from eight Asian countries from 
June 2011–April 2012. This Asian study has followed an 
almost identical protocol and case record forms as in our 
EPICOR study.
Statistical methods
We identified over 50 candidate variables for prediction 
(patient history, at admission, during admission, and at dis-
charge), and these are listed in Appendix 1. From these a 
new risk score for one-year mortality post discharge was 
developed using Cox proportional hazard models. The sta-
tistical approach for model building was forward stepwise 
variable selection, with a criterion of p<0.01 for variable 
inclusion. For continuous predictors, checks were under-
taken for non-linearity and, if found appropriate, re- 
modelling of such variables was conducted e.g. either using 
a binary cut-off (e.g. hemoglobin, blood glucose) or by 
expressing as a linear trend above a certain level (e.g. serum 
creatinine). In combining predictors for patients with 
STEMI and with NSTE-ACS it is important to explore evi-
dence of statistical interactions with other predictors. On 
the whole, most variables selected showed a similar magni-
tude of risk prediction for both STEMI and NSTE-ACS 
patients. The one exception was that the increased risk of 
not receiving coronary revascularization during hospitali-
zation was more marked in NSTE-ACS patients.
Some prognostic variables were missing in a small 
minority of patients. To overcome this problem, thereby 
enabling all patients’ available data to be validly used, a 
multiple imputation method was used based on a recently 
developed extension of the chained equations approach.11
Most predictor variables identified (see Table 1) are well 
understood, but the novel use of the EuroQoL EQ-5D 
requires explanation. This questionnaire evaluates five 
issues: patient mobility, self-care, usual activities, pain/dis-
comfort and anxiety/depression. For each there is specific 
wording to elicit whether the patient has no, moderate, or 
severe limitation. For each we have scored 0, 1 or 2 points 
respectively, and adding up these scores yields a simple 
overall score ranging from 0 points up to a maximum of 10 
points. While there do exist more complex weighted 
schemes for handling the EQ-5D,12 we feel that for practi-
cal use in our context of user-friendly risk prediction this 
required the adoption of such simple scoring.
The multiple imputations were performed using Stata 
12.0 while all other analyses used SAS version 9.2.
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Results
The study cohort comprises 10,568 consecutive hospital 
survivors after an ACS event (4943 STEMI and 5625 
NSTE-ACS). Four hundred and seven patients (3.9%) died 
within one year of discharge while 242 (2.3%) were lost to 
follow-up.
From all of the candidate variables available, a Cox pro-
portional hazard model was used with forward stepwise 
variable selection to identify 12 highly significant inde-
pendent predictors of one-year mortality. These are 
described in Table 1 along with geographic region.
Table 2 presents the multivariable predictive model 
which simultaneously uses all 12 risk variables to produce 
Table 1. Descriptive statistics for key baseline variables.
STEMI patients NSTE-ACS patients All Deaths
No. of patients 4943 5625 10,568 3.9%
 STEMI 4943 3.1%
 NSTE-ACS 5625 4.5%
Age, years, mean (SD) 59.4 (12.1) 63.8 (12.1) 61.8 (12.3)  
Gender  
 Male 3924 3996 7920 3.7%
 Female 1019 1629 2648 4.3%
Ejection fraction at admissiona  
 Normal ≥40% 4035 4641 8676 2.9%
 Moderately reduced 30–39% 459 329 788 9.0%
 Severely reduced <30% 112 126 238 22.7%
Cardiac complications in hospital  
 MI or recurrent ischemia 258 342 600 6.7%
 Cardiogenic shock 85 24 109 7.3%
 Heart failure 327 289 616 12.8%
 Any arrhythmia 589 425 1014 6.4%
 Any of the above 1019 915 1934 7.6%
Serum creatinine at admission,a mg/dl, mean (SD) 0.96 (0.42) 1.04 (0.59) 1.00 (0.52)  
 ≥1.2 mg/dl 650 1060 1710 8.9%
High blood glucose (≥160 mg/dl) at admissiona 1134 1035 2169 6.0%
Low hemoglobin (<13 g/dl) at admissiona 891 1328 2219 6.9%
COPD or other chronic lung disease 256 427 683 8.8%
Peripheral vascular disease 145 384 529 11.0%
On diuretics at discharge 683 1283 1966 8.5%
Interventions during admission  
 CABG or PCI 3863 3285 7148 2.6%
 Neither 1080 2340 3420 7.1%
Simple EQ-5D score at dischargea  
 0, no problems 2392 2382 4774 2.4%
 1 1049 1157 2206 3.2%
 2 576 785 1361 4.4%
 3 335 485 820 4.7%
 4 211 325 536 8.4%
 ≥5, severe problems 226 345 571 11.9%
Geographic region  
 Northern Europe 1608 2174 3782 2.5%
 Southern Europe 1124 1213 2337 3.6%
 Eastern Europe 1145 1235 2380 4.8%
 Latin America 1066 1003 2069 5.5%
CABG: coronary artery bypass graft; COPD: chronic obstructive pulmonary disease; MI: myocardial infarction; NSTE-ACS: non-ST-elevation ACS; 
PCI: percutaneous coronary intervention; SD: standard deviation; STEMI: ST-segment elevation myocardial infarction.
a Indicates variables with missing data as follows: ejection fraction (8.2% missing), serum creatinine (5.6%), blood glucose (13.2%), hemoglobin (6.7%), 
EQ-5D (2.8%). Multiple imputation was used to overcome this: see statistical methods section.
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an overall risk score. Variables in Table 2 are listed in order 
of their statistical significance (age is the strongest predic-
tor) and each hazard ratio is adjusted for all the other vari-
ables. One statistical interaction was identified: for 
NSTE-ACS patients only, those who received percutaneous 
coronary intervention (PCI) or coronary artery bypass graft 
(CABG) during this admission had a lower mortality than 
those on medication only. For continuous variables, poten-
tial non-linearity in the prediction of survival was explored. 
Hence the increasing impact of serum creatinine on mortal-
ity was confined to values above 1.2 mg/dl while for blood 
glucose and hemoglobin binary cut-offs of ≥160 mg/dl and 
<13 g/dl were respectively used.
Figure 1 displays the independent impact of each predic-
tor on mortality risk. In addition, there remain substantial 
regional differences in one-year mortality not explained by 
these predictors: Eastern Europe and Latin American have 
adjusted hazard ratios of 2.15 and 2.10, respectively, com-
pared with Western Europe (North).
From the risk coefficients in Table 2, the multivariable 
risk score is readily calculated for each patient and its dis-
tribution (×10) is shown in Figure 2. The curve in Figure 2 
relates a patient’s score to the probability of dying within 
one year of discharge. Good discrimination is achieved 
with c-statistic=0.81.
Figure 3 shows the cumulative mortality over one year 
for patients classified into six risk groups. Groups 1–4 
comprise the bottom four quintiles of risk while groups 5 
and 6 are the top two deciles of risk. While all six groups 
are clearly separated, the absolute magnitude of differ-
ences between risk groups is much more marked for the 
top two deciles, with 6.3% and 18.2% one-year mortality, 
respectively. This contrasts with 0.5% one-year mortality 
in the lowest quintile.
Regarding model goodness-of-fit, Figure 4(a) compares 
observed and model-predicted one-year mortality risk 
across the six risk groups.
Table 3 shows two separate models for STEMI and 
NSTE-ACS patients. For nearly all predictors, the strength 
of mortality association is similar in both subgroups. 
However, the lower risk if coronary revascularization 
occurred during admission is more notable in NSTE-ACS 
patients, and this statistical interaction is captured in the 
main predictive model in Table 2.
For STEMI patients we investigated the impact of rapid 
time to admission (or time to reperfusion) on reducing mor-
tality after discharge. There were 697 STEMI patients 
(14%) admitted within one hour of symptom onset: hazard 
ratio 0.44 (p=0.026) compared to other STEMI patients. 
Also, 1316 STEMI patients (27%) had reperfusion within 
two hours of symptom onset: hazard ratio 0.64 (p=0.053) 
compared to other STEMI patients. These findings were of 
borderline statistical significance so these two variables 
were not included in the main predictive model.
In order to validate our main model on an external 
cohort, we used the 9907 patients in the EPICOR Asia reg-
istry who had complete data on all variables listed in Table 
2, of whom 3.1% died within one year of hospital discharge. 
Figure 4(b) compares the observed and model-predicted 
mortality in six risk groups (from lowest quintile to top 
decile). The model fit and extent of risk discrimination is 
very similar to what was found in our original cohort. The 
c-statistic in EPICOR Asia patients is 0.784, only slightly 
less than the c=0.81 achieved in model development.
Table 2. Multivariate analysis of one-year mortality: final model for all patients (with missing data imputed).
Variable All patients
Coefficient HR 95% CI p-value
Age (per 10 years) 0.43 1.54 1.40–1.70 <0.00001
Ejection fraction <40%a 0.62 1.87 1.42–2.46 <0.0001
Ejection fraction <30%a 1.35 3.84 2.80–5.27 <0.0001
EQ-5D score (per unit) 0.15 1.16 1.10–1.21 <0.0001
Serum creatinine (per unit ≥1.2 mg/dl)a 0.22 1.25 1.13–1.38 <0.0001
Cardiac complication in hospital 0.41 1.50 1.21–1.86 0.0002
Blood glucose ≥160 mg/dla 0.39 1.48 1.19–1.84 0.0004
COPD 0.52 1.68 1.26–2.24 0.0004
Male gender 0.40 1.49 1.18–1.89 0.0009
NSTE-ACS with meds onlyb 0.39 1.47 1.17–1.86 0.0012
NSTE-ACS with PCI/CABGb –0.22 0.80 0.61–1.05 0.1117
Hemoglobin <13 g/dla 0.35 1.42 1.13–1.80 0.0029
Peripheral vascular disease 0.45 1.57 1.17–2.10 0.0029
On diuretics at discharge 0.30 1.35 1.08–1.70 0.0095
CABG: coronary artery bypass graft; CI: confidence interval; COPD: chronic obstructive pulmonary disease; HR: hazard ratio; NSTE-ACS: non-ST-
elevation ACS; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction.
aAt admission; bas compared to STEMI.
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Figure 1. Mortality hazard ratios for each variable in the predictive model. CABG: coronary artery bypass graft; CI: confidence 
interval; COPD: chronic obstructive pulmonary disease; NSTE-ACS: non-ST-elevation acute coronary syndrome; PCI: percutaneous 
coronary intervention; STEMI: ST segment elevation myocardial infarction.
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Discussion
The findings we present are based on a large international 
prospective real-world cohort study comprising consecutive 
patients hospitalized from an ACS event within 24 h of 
symptoms onset who survived to hospital discharge. Such a 
representative population across Europe and Latin America 
is therefore uniquely well placed to quantify the independent 
determinants of mortality risk over one year post-discharge.
The 12 highly significant predictors we identified should 
all be readily available in routine clinical practice. To facili-
tate the quantification of individual risk we provide a web 
calculator www.acsrisk.org thus avoiding the burden of 
numerical calculations.
There is a marked identifiable variation in individual 
patient risk (see Figure 4). This means a sizeable proportion 
of patients can be classified as low risk, e.g. around half 
have a one-year mortality risk <1%. On the other hand 10% 
of patients have a high one-year mortality risk (see Figures 
2 and 3). Knowing this fact, based on our risk model, should 
help in supporting appropriate patient management.
The contributions made by each specific predictor are 
worth noting. Not surprisingly, age has the most profound 
influence on mortality risk, followed by reduced ejection 
fraction. A more novel contributor to risk assessment is 
quality of life at discharge, using a simple score derived 
from the EuroQoL EQ-5D.13 Across five aspects (mobility, 
self-care, usual activities, pain/discomfort, anxiety/discom-
fort) we add one point for moderate impairment or two 
points for severe impairment. Patients scoring four points 
or more (11%) had more than double the mortality risk of 
patients with no impairment (45%), with a gradient of risk 
for patients in between these two extremes. Thus, a poor 
functional quality of life may be expressing some level of 
frailty and a mortality risk that is not captured by other 
predictors.
The 4943 STEMI patients had a lower one-year mortal-
ity after discharge compared to the 5625 NSTE-ACS 
patients: 3.1% vs 4.5% died, respectively. However, after 
adjustment for the other 11 risk factors, the hazard ratio 
became 1.00 (95% CI 0.80–1.24). This reflects that NSTE-
ACS had a higher prevalence of other risk factors (see 
Table 1). Indeed, NSTE-ACS contributes over twice as 
many patients in the top decile of risk compared to STEMI. 
However, for NSTE-ACS patients only, one notable con-
tributor to risk was not having PCI or CABG during hospi-
tal stay: hazard ratio 1.84 after adjustment for other risk 
factors. Thus, lack of coronary revascularization reflects an 
anticipated poorer prognosis post-discharge. This may be 
Figure 2. Risk score distribution (and predicted mortality risk).
Figure 3. Cumulative mortality in six risk groups. Risk 
groups 1–4 correspond to quintiles 1–4, with the fifth quintile 
subdivided into two deciles (risk groups 5 and 6).
Figure 4. Assessment of risk discrimination and model 
goodness-of-fit in six groups from low to very high risk (a) 
In original EPICOR (long-tErm follow uP of antithrombotic 
management patterns In acute CORonary syndrome patients) 
study and (b) In EPICOR Asia (validation cohort). For both 
plots, risk groups 1–4 correspond to quintiles 1–4, with the fifth 
quintile subdivided into two deciles (risk groups 5 and 6).
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explained by either the actual risk benefit of coronary 
revascularization or selection bias (i.e. poor risk patients 
are deemed not appropriate for intervention).14
From blood samples at admission, contributions to 
higher risk are represented by raised creatinine, raised glu-
cose and lower hemoglobin. For disease history, both 
chronic obstructive pulmonary disease and peripheral vas-
cular disease increased risk, indicating that conditions other 
than cardiac disease carry a mortality risk. Cardiac compli-
cations during the admission were associated with a 50% 
increase in mortality risk. Also, men had a 50% higher risk 
than women after all other risk factors were accounted for. 
In univariate analysis women have a higher one-year mor-
tality than men (4.3% vs 3.7%). But women are more prone 
to having other risk factors (e.g. older age) so that in the 
multivariable model being female independently predicts a 
lower risk. Lastly, being on diuretics at discharge was an 
indicator of 35% higher mortality risk.
Confidence in the generalizability of any new risk model 
is much enhanced if it is validated on an external popula-
tion. Here, the EPICOR Asia study has provided similar 
risk discrimination and goodness of fit (compare the two 
plots in Figure 4), as summarized by the c-statistic of 0.78 
in Asian patients compared to 0.81 in the original cohort. 
Given that the two studies were from different geographic 
regions, this provides assurance that our risk model may 
well be of global applicability.
In external validation some reduction in c-statistic is 
always to be expected on statistical grounds i.e. risk coef-
ficients in any model are optimized by the maximum likeli-
hood principle of any model fit, so the true strength of 
prediction is inevitably slightly less in another independent 
data set. To further explore model fit in the Asian cohort we 
did another Cox regression model with the same 12 predic-
tor variables: the hazard ratios of all but one variable were 
very similar to those reported in our original EPICOR 
model (Table 2). The one exception was peripheral vascular 
disease which was very uncommon in the Asian cohort so 
that its hazard ratio had a wide CI. This consistency of find-
ings suggests that there is little effect of ethnic diversity on 
risk prediction.
While there exist several other risk scores for patients 
with ACS, most do not focus on risk from the time of hos-
pital discharge and hence are not appropriate for compari-
son here. However, Eagle et al. have used the Global 
Registry of Acute Coronary Events (GRACE) registry to 
estimate mortality risk six months post discharge.7 Their 
risk calculator includes nine predictors: age, history of con-
gestive heart failure, history of MI, increased heart rate at 
admission, lower systolic blood pressure at admission, ele-
vated serum creatinine at admission, elevated cardiac 
enzymes, ST-segment depression, and no in- 
hospital PCI. This achieved a similar predictive strength to 
the current model (c-statistic = 0.81 at development, 0.75 at 
validation). However, the shorter time period could be a 
limiting factor. Their six-month mortality rate (4.8%) is 
higher than our one-year mortality rate (3.9%), perhaps 
reflecting the fact that their cohort is from around 10 years 
ago. Also, the mortality rate in EPICOR might not include 
high-risk patients transferred to other units for non-cardiac 
complications or needing longer-term care. It would be use-
ful if the GRACE and EPICOR risk models were directly 
compared in an independent cohort of ACS patients fol-
lowed from hospital discharge.
There are some limitations inherent to our risk model. 
Being a study on hospital survivors, blood pressure and 
Table 3. Separate models for ST-segment elevation myocardial infarction (STEMI) and non-ST-elevation acute coronary syndrome 
(NSTE-ACS) patients.
Variable STEMI patients NSTE–ACS patients
 HR 95% CI HR 95% CI
Age (per 10 years) 1.56 1.34–1.80 1.52 1.34–1.73
Ejection fraction <40%a 1.42 0.89–2.27 2.29 1.62–3.24
Ejection fraction <30%a 3.73 2.17–6.41 4.03 2.69–6.02
EQ-5D score (per unit) 1.18 1.09–1.28 1.14 1.07–1.22
Serum creatinine (per unit ≥1.2 mg/dl)a 1.27 1.04–1.55 1.23 1.09–1.38
Cardiac complication in hospital 1.15 0.80–1.65 1.73 1.33–2.27
Blood glucose ≥160 mg/dla 1.29 0.91–1.84 1.64 1.24–2.16
COPD 1.60 0.96–2.68 1.71 1.20–2.43
Male gender 1.47 0.98–2.22 1.54 1.14–2.06
PCI/CABG during admission 0.73 0.52–1.04 0.52 0.40–0.69
Hemoglobin <13 g/dla 1.57 1.05–2.35 1.33 1.00–1.78
Peripheral vascular disease 1.47 0.76–2.86 1.55 1.10–2.18
On diuretics at discharge 1.43 0.97–2.11 1.29 0.97–1.73
CABG: coronary artery bypass graft; CI: confidence interval; COPD: chronic obstructive pulmonary disease; HR: hazard ratio; PCI: percutaneous 
coronary intervention. aAt admission.
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heart rate at admission were not recorded in our database 
and hence could not be included in the model. Certain other 
variables (e.g. probrain natiuretic peptide, incomplete revas-
cularization) were also not available for inclusion. Even 
after taking account of our 12 highly predictive risk factors, 
there persist substantial unexplained geographic differences 
in post-discharge mortality risk. In Eastern Europe and Latin 
America one-year mortality is markedly higher than in 
Western Europe, and further investigation is needed to clar-
ify why this discrepancy exists.
This geographic heterogeneity could be perceived as a 
limitation but given the intention of any risk model is that it 
be useful in many different countries we feel our popula-
tion’s geographic diversity is an asset in enhancing general-
izability. We intend to publish further on the geographic 
regional differences in the distribution (prevalence) of risk 
factors, both in the EPICOR and EPICOR-Asia cohorts.
One could argue that STEMI and NSTE-ACS are suffi-
ciently different conditions that two separate risk models 
should be developed. However, as shown in Table 3 there is 
substantial consistency of risk prediction for the 12 varia-
bles (i.e. mostly similar hazard ratios) so that for practical 
purposes we feel a single overall risk model is desirable.
Another limitation is that with over 50 candidate predic-
tor variables there is a risk of a “false positive” predictor 
entering the risk model. However with p<0.01 as entry cri-
terion this risk is relatively low. The one novel predictor is 
the EQ-5D score, but this is very highly significant. The 
rest are to be expected on the basis of prior studies of mor-
tality risk in ACS patients.
While the design of EPICOR was geared to recruiting 
representative patients from representative centers in each 
country, we cannot directly verify that centers are indeed 
representative in respect to adherence to treatment guide-
lines and other aspects of patient management. Thus some 
caution is warranted with respect to extrapolation of find-
ings to the overall population of ACS patients.
In conclusion, we have documented how post-discharge 
mortality risk after an ACS event varies markedly. 
Individual one-year mortality can be reliably estimated 
using 12 readily available items, and the consequent risk 
discrimination and model fit are good. User-friendly access 
to our risk model is available via the web: www.acsrisk.org. 
We feel this tool can help influence appropriate patient 
management post discharge, especially in identifying indi-
viduals at higher risk for whom more intensive monitoring 
may be appropriate.
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Appendix 1. A list of candidate predictor variables
Demographics and medical history Variables collected during admission
Gender Time from symptom onset to admission
Age Time from admission to reperfusion
Race Time from symptom onset to reperfusion
Education level Length of hospital stay
Professional status Killip class
Height Diagnosis (STEMI, NSTEMI, unstable 
angina)
Weight Left bundle branch block
Body mass index Ejection fractiona
Hypertension White blood counta
Hypercholesterolemia Creatininea
Diabetes Glucosea
Family history of CAD Hemoglobina
Smoking PCI during admission
Previous MI CABG during admission
Prior PCI Reperfusion (PCI at thrombolysis)
Prior CABG No. of dilated vessels
Chronic angina Any drug eluting stent
Prior heart failure No. of antiplateletsb
Prior atrial fibrillation Anticoagulantb
Prior transient ischemic attack/stroke Beta blockerb
Prior peripheral vascular disease Angiotensin-converting enzyme inhibitor/
angiotensin receptor blockerb
Chronic renal failure Diureticsb
COPD or other chronic lung disease Aldosterone inhibitorb
 Calcium-channel blockerb
 Ischemic complications
 Cardiogenic shock
 Heart failure
 Dyspnea
 Arrhythmia
 Dependence at discharge
 EQ-5D overall health state at discharge
 EQ-5D simple score at discharge
COPD: chronic obstructive pulmonary disease;
aAt admission; bat discharge.
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